上海萊士(002252.SZ):截至目前,公司及下屬子公司、孫公司擁有單採血漿站42家
格隆匯6月14日丨上海萊士(002252.SZ)在2023年6月13日接受特定對象調研時表示,公司整體規模為國內血液製品行業領先,是國內同行業中結構合理、產品種類齊全、血漿利用率較高的領先血液製品生產企業之一。公司目前共有上海、鄭州、合肥、温州4個血液製品生產基地,產品已經覆蓋了白蛋白類、免疫球蛋白類及凝血因子三大類,是目前國內少數可從血漿中提取六種組分的血液製品生產企業之一,也是國內同行業中凝血因子類產品種類最為齊全的生產企業之一。截至目前,公司及下屬子公司、孫公司擁有單採血漿站42家,分佈於廣西、湖南、海南、陝西、安徽、廣東、內蒙、浙江、湖北、江西、山東11個省(自治區),漿站數量、分佈區域及全年採漿量均位居行業前列。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.